Search

Your search keyword '"Vigneron, Paul"' showing total 7 results
Start Over Author "Vigneron, Paul"
7 results on '"Vigneron, Paul"'

2. FRI-456 Characterization of the intratumoral immune microenvironment of hepatocellular carcinoma before selective intrahepatic radiation therapy (SIRT) and study of its prognostic value on response to treatment

Author

Franzè, Maria Stella, primary, Vigneron, Paul, additional, Caruso, Stefano, additional, Regnault, Hélène, additional, Sessa, Anna, additional, Maille, Pascale, additional, Bouda, Yasmine, additional, Iavarone, Massimo, additional, Canova, Lorenzo, additional, Maggioni, Marco, additional, Khac, Eric Nguyen, additional, Sarba, Ruxandra, additional, Yzet, Thierry, additional, Heurgue-berlot, Alexandra, additional, Kianmanesh, Reza, additional, Rhaiem, Rami, additional, Nault, Jean Charles, additional, Soussan, Michael, additional, Sutter, Olivier, additional, Allaire, Manon, additional, Lequoy, Marie, additional, Bouattour, Mohamed, additional, Beaufrère, Aurélie, additional, Burgio, Marco Dioguardi, additional, Raffaele, Brustia, additional, Sommacale, Daniele, additional, Luciani, Alain, additional, Tacher, Vania, additional, Pawlotsky, Jean-Michel, additional, Leroy, Vincent, additional, Calderaro, Julien, additional, and Amaddeo, Giuliana, additional

Published
2024
Full Text
View/download PDF

3. Selective internal radiation therapy across Barcelona Clinic Liver Cancer (BCLC) stages of hepatocellular carcinoma: literature review

Author

Vigneron, Paul, primary, Franzè, Maria Stella, additional, Chalaye, Julia, additional, Tacher, Vania, additional, Sessa, Anna, additional, Luciani, Alain, additional, Kobeiter, Hicham, additional, Regnault, Hélène, additional, Bejan, Ancuta, additional, Calderaro, Julien, additional, Rhaiem, Rami, additional, Sommacale, Daniele, additional, Raimondo, Giovanni, additional, Leroy, Vincent, additional, Brustia, Raffaele, additional, and Amaddeo, Giuliana, additional

Published
2023
Full Text
View/download PDF

4. Systemic treatments with tyrosine kinase inhibitors and platinum-based chemotherapy in patients with unresectable or metastatic hepato-cholangiocarcinoma

Author

Gigante, Elia, primary, Hobeika, Christian, additional, Le Bail, Brigitte, additional, Paradis, Valérie, additional, Tougeron, David, additional, Lequoy, Marie, additional, Bouattour, Mohamed, additional, Blanc, Jean-Frédéric, additional, Ganne-Carrié, Nathalie, additional, Tran, Henri, additional, Hollande, Clemence, additional, Allaire, Manon, additional, Amaddeo, Giuliana, additional, Regnault, Helene, additional, Vigneron, Paul, additional, Ronot, Maxime, additional, Elkrief, Laure, additional, Verset, Gontran, additional, Trepo, Eric, additional, Zaanan, Aziz, additional, Ziol, Marianne, additional, Ningarhari, Massih, additional, Calderaro, Julien, additional, Edeline, Julien, additional, and Nault, Jean Charles, additional

Published
2022
Full Text
View/download PDF

5. Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma.

Author

Gigante, Elia, Hobeika, Christian, Le Bail, Brigitte, Paradis, Valérie, Tougeron, David, Lequoy, Marie, Bouattour, Mohamed, Blanc, Jean Frédéric, Ganne-Carrié, Nathalie, Tran, Henri, Hollande, Clémence, Allaire, Manon, Amaddeo, Giuliana, Regnault, Hélène, Vigneron, Paul, Ronot, Maxime, Elkrief, Laure, Verset, Gontran, Trepo, Eric, Zaanan, Aziz, Ziol, Marianne, Ningarhari, Massih, Calderaro, Julien, Edeline, Julien, Nault, Jean Charles, Gigante, Elia, Hobeika, Christian, Le Bail, Brigitte, Paradis, Valérie, Tougeron, David, Lequoy, Marie, Bouattour, Mohamed, Blanc, Jean Frédéric, Ganne-Carrié, Nathalie, Tran, Henri, Hollande, Clémence, Allaire, Manon, Amaddeo, Giuliana, Regnault, Hélène, Vigneron, Paul, Ronot, Maxime, Elkrief, Laure, Verset, Gontran, Trepo, Eric, Zaanan, Aziz, Ziol, Marianne, Ningarhari, Massih, Calderaro, Julien, Edeline, Julien, and Nault, Jean Charles

Abstract

Even if no systemic treatment is currently validated for unresectable hepatocellular-cholangiocarcinoma (cHCC-CCA), tyrosine kinase inhibitors (TKIs) and platinum-based chemotherapy are frequently used in clinical practice. Our study aims to describe the effectiveness of first-line systemic treatments in patients with cHCC-CCA., info:eu-repo/semantics/published

Published
2022

6. Systemic Treatments with Tyrosine Kinase Inhibitor and Platinum-Based Chemotherapy in Patients with Unresectable or Metastatic Hepatocholangiocarcinoma

Author

Gigante, Elia, primary, Hobeika, Christian, additional, Le Bail, Brigitte, additional, Paradis, Valérie, additional, Tougeron, David, additional, Lequoy, Marie, additional, Bouattour, Mohamed, additional, Blanc, Jean-Frederic, additional, Ganne-Carrié, Nathalie, additional, Tran, Henri, additional, Hollande, Clémence, additional, Allaire, Manon, additional, Amaddeo, Giuliana, additional, Regnault, Hélène, additional, Vigneron, Paul, additional, Ronot, Maxime, additional, Elkrief, Laure, additional, Verset, Gontran, additional, Trepo, Eric, additional, Zaanan, Aziz, additional, Ziol, Marianne, additional, Ningarhari, Massih, additional, Calderaro, Julien, additional, Edeline, Julien, additional, and Nault, Jean-Charles, additional

Published
2022
Full Text
View/download PDF

7. Prognostic factors influencing outcomes in hepatocellular carcinoma patients undergoing selective internal radiation therapy.

Author

Franzè MS, Vigneron P, Sessa A, Saitta C, Chalaye J, Tacher V, Luciani A, Regnault H, Bejan A, Rhaiem R, Sommacale D, Leroy V, Brustia R, Raimondo G, and Amaddeo G

Abstract

Selective internal radiation therapy (SIRT) has emerged as a viable endovascular treatment strategy for hepatocellular carcinoma (HCC). According to the Barcelona Clinic Liver Cancer (BCLC) classification, SIRT is currently recommended for early- and intermediate-stage HCC that is unsuitable for alternative locoregional therapies. Additionally, SIRT remains a recommended treatment for patients with advanced-stage HCC and portal vein thrombosis (PVT) without extrahepatic metastasis. Several studies have shown that SIRT is a versatile and promising treatment with a wide range of applications. Consequently, given its favourable characteristics in various scenarios, SIRT could be an encouraging treatment option for patients with HCC across different BCLC stages. Over the past decade, an increasing number of studies have focused on better understanding the prognostic factors associated with SIRT to identify patients who derive the most benefit from this treatment or to refine the optimal technical procedures of SIRT. Several variables can influence treatment decisions, with a growing emphasis on a personalised approach. This review, based on the literature, will focus on the prognostic factors associated with the effectiveness of radioembolization and related complications. By comprehensively analysing these factors, we aimed to provide a clearer understanding of how to optimise the use of SIRT in managing HCC patients, thereby enhancing outcomes across various clinical scenarios., Competing Interests: Conflicts of interest None., (Copyright © 2024 Fundación Clínica Médica Sur, A.C. Published by Elsevier España, S.L.U. All rights reserved.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results